INC280
Total Payments
$3.0M
Transactions
273
Doctors
35
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $728,860 | 59 | 10 |
| 2019 | $589,733 | 56 | 4 |
| 2018 | $792,785 | 60 | 1 |
| 2017 | $914,831 | 98 | 22 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 247 | 100.0% |
| Food and Beverage | $815.53 | 26 | 0.0% |
Payments by Type
Research
$3.0M
247 transactions
General
$815.53
26 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE II MULTICENTER THREE COHORT STUDY OF ORAL CMET INHIBITOR INC280 IN ADULT PATIENTS WITH EGFR WILD TYPE WT ADVANCED NON SMALL CELL LUNG CANCER NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FORADVANCED METASTATIC DISEASE | Novartis Pharmaceuticals Corporation | $1.7M | 0 |
| A PHASE IB AND OR II OPEN LABEL MULTICENTER TRIAL WITH ORAL CMET INHIBITOR INC280 ALONE AND IN COMBINATION WITH ERLOTINIB VERSUS PLATINUM AND OR PEMETREXED IN ADULT PATIENTS WITH EGFR MUTATED CMET AMPLIFIED LOCALLY ADVANCED AND OR METASTATIC NONSMALL CELL LUNG CANCER NSCLC WITH ACQUIRED RESISTANCE TO PRIOR EGFR TYROSINE KINASE INHIBITOR EGFR TKI | Novartis Pharmaceuticals Corporation | $278,906 | 0 |
| PHASE II STUDY OF INC280 IN NSCLC PATIENTS WITH MET EXON 14 SKIPPING ALTERATIONS METEX14 AND PRIOR MET INHIBITOR EXPOSURE | Novartis Pharmaceuticals Corporation | $202,600 | 0 |
| A PHASE I AND OR II MULTICENTER OPEN LABEL STUDY OF EGFRMUT TKI EGF816 IN COMBINATION WITH INC280 ADMINISTERED ORALLY IN ADULT PATIENTS WITH NSCLC EGFRMUT | Novartis Pharmaceuticals Corporation | $182,048 | 0 |
| A PHASE II MULTICENTER RANDOMIZED TWO ARM STUDY OF THE COMBINATION OF CAPMATINIB INC280 AN ORAL MET INHIBITOR AND SPARTALIZUMAB PDR001 A PD 1 INHIBITOR VERSUS DOCETAXEL IN PRETREATED ADULT PATIENTS WITH EGFR WILD TYPE ALK REARRANGEMENT NEGATIVE LOCALLY AD | Novartis Pharmaceuticals Corporation | $107,307 | 0 |
| AN OPEN-LABEL, MULTI-CENTER, GLOBAL, ROLLOVER STUDY FOR PATIENTS WHO HAVE PREVIOUSLY BEEN TREATED WITH CAPMATINIB (INC280) AS MONOTHERAPY OR IN COMBINATION IN A NOVARTIS SPONSORED TRIAL | Novartis Pharmaceuticals Corporation | $89,313 | 0 |
| A PHASE IB AND OR II OPEN LABEL MULTICENTER TRIAL WITH ORAL CMET INHIBITOR INC280 ALONE AND IN COMBINATION WITH ERLOTINIB VERSUS PLATINUM AND OR PEMETREXED IN ADULT PATIENTS WITH EGFR MUTATED CMET AMPLIFIED LOCALLY ADVANCED AND OR METASTATIC NONSMALL CELL | Novartis Pharmaceuticals Corporation | $84,520 | 0 |
| AN OPEN LABEL SINGLE DOSE MULTI CENTER PARALLEL GROUP TWO STAGED STUDY TO EVALUATE THE PHARMACOKINETICS OF THE ORAL CMET INHIBITOR INC280 IN NON CANCER SUBJECTS WITH IMPAIRED HEPATIC FUNCTION AND NON CANCER SUBJECTS WITH NORMAL HEPATIC FUNCTION | Novartis Pharmaceuticals Corporation | $64,260 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $57,302 | 7 |
| A PHASE I STUDY OF INC280 PLUS ERLOTINIB IN PATIENTS WITH CMET DEPENDENT ADVANCED CANCER WITH AN EMPHASIS IN NON SMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $55,030 | 0 |
| A MULTICENTER OPEN LABEL PHASE 1 DOSE ESCALATION STUDY TO EVALUATE THE PHARMACOKINETICS SAFETY AND TOLERABILITY OF INC280 TABLET FORMULATION WITH FOOD IN PATIENTS WITH CMET DYSREGULATED ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $48,939 | 0 |
| A PHASE I MULTICENTER OPEN LABEL SINGLE SEQUENCE DRUGDRUG INTERACTION STUDY TO ASSESS THE EFFECT OF INC280 ON THE PHARMACOKINETICS OF MIDAZOLAM AND CAFFEINE IN PATIENTS WITH CMET DYSREGULATED ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $36,595 | 0 |
| A PHASE I OPEN LABEL DOSE ESCALATION STUDY WITH EXPANSION TO ASSESS THE SAFETY AND TOLERABILITY OF INC280 IN PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $32,143 | 0 |
| A PHASE IB AND OR II OPEN LABEL MULTICENTER STUDY OF INC280 INCOMBINATION WITH BUPARLISIB IN ADULT PATIENTS WITH RECURRENTGLIOBLASTOMA | Novartis Pharmaceuticals Corporation | $31,820 | 0 |
| A PHASE I MULTICENTER OPEN LABEL SINGLE SEQUENCE DRUG INTERACTION STUDY TO ASSESS THE EFFECT OF INC280 ON THE PHARMACOKINETICS OF DIGOXIN AND ROSUVASTATIN IN PATIENTS WITH CMET DYSREGULATED ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $28,410 | 0 |
| A PHASE IB II OPEN LABEL MULTI CENTER STUDY OF INC280 IN COMBINATION WITH PDR001 OR PDR001 SINGLE AGENT IN ADVANCED HEPATOCELLULAR CARCINOMA | Novartis Pharmaceuticals Corporation | $27,475 | 0 |
| A RANDOMIZED PHASE II DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OFINC280 IN ADULT PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA AFTER PROGRESSION OR INTOLERANCE TO SORAFENIBTREATMENT | Novartis Pharmaceuticals Corporation | $14,000 | 0 |
| A PHASE II MULTICENTER THREE COHORT STUDY OF ORAL CMET INHIBITOR INC280 IN ADULT PATIENTS WITH EGFR WILD TYPE WT ADVANCED NON SMALL CELL LUNG CANCER NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FORADVANCED METASTATIC DISEASE | NOVARTIS PHARMACEUTICALS CORPORATION | $5,794 | 0 |
| A PHASE IB OPEN LABEL MULTICENTER DOSE ESCALATION AND EXPANSION COHORT STUDY TO EVALUATE THE SAFETY PHARMACOKINETICS AND ACTIVITY OF INC280 IN COMBINATION WITH CETUXIMAB IN CMET PLUS CRC AND HNSCC PATIENTS WHO HAVE PROGRESSED AFTER ANTI EGFR MONOCLONAL AN | Novartis Pharmaceuticals Corporation | $1,109 | 0 |
| QUALITATIVE RESEARCH TO EXPLORE THE EXPERIENCES OF PATIENTS WITH NON?SMALL CELL LUNG CANCER AND BRAIN METASTASES | Novartis Pharmaceuticals Corporation | $1,050 | 3 |
Top Doctors Receiving Payments for INC280
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Camp Hill, PA | $3.0M | 234 |
| , M.D.,PHD | Anatomic Pathology & Clinical Pathology | Kansas City, KS | $13,125 | 1 |
| , MD | Hematology | Kansas City, MO | $13,125 | 1 |
| , MD | Hematology & Oncology | Nashville, TN | $8,750 | 1 |
| , MD PHD | Hematology & Oncology | Cleveland, OH | $8,750 | 1 |
| , MD | Hematology & Oncology | Orlando, FL | $8,750 | 1 |
| , MD | Hematology & Oncology | Los Angeles, CA | $2,447 | 3 |
| , MD MPH | Medical Oncology | Boston, MA | $2,401 | 2 |
| , MD | Hematology & Oncology | Chapel Hill, NC | $350.00 | 1 |
| , MD | Medical Oncology | Aurora, CO | $350.00 | 1 |
| , M.D., M.S | Internal Medicine | Sacramento, CA | $350.00 | 1 |
| , MD | Medical Oncology | Houston, TX | $143.25 | 1 |
| , M.D | Hematology & Oncology | La Jolla, CA | $122.67 | 1 |
| , M.D | Hospice and Palliative Medicine | Madison, WI | $86.81 | 1 |
| , MD | Medical Oncology | Stanford, CA | $86.81 | 1 |
| , M.D., PH.D | Hematology & Oncology | Stanford, CA | $86.81 | 1 |
| , M.D | Internal Medicine | Santa Monica, CA | $46.00 | 1 |
| , D.O | Hematology & Oncology | Springfield, OR | $39.72 | 1 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $27.97 | 2 |
| , MD | Internal Medicine | New York, NY | $23.35 | 1 |
| , M.D | Internal Medicine | Irving, TX | $20.37 | 1 |
| , MD | Medical Oncology | Loma Linda, CA | $20.37 | 1 |
| , M.D | Hematology & Oncology | Loma Linda, CA | $20.37 | 1 |
| , M.D | Medical Oncology | Loma Linda, CA | $20.37 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Loma Linda, CA | $20.37 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.0M
- Total Doctors 35
- Transactions 273
About INC280
INC280 is a drug associated with $3.0M in payments to 35 healthcare providers, recorded across 273 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $728,860 was paid across 59 transactions to 10 doctors.
The most common payment nature for INC280 is "Unspecified" ($3.0M, 100.0% of total).
INC280 is associated with 20 research studies, including "A PHASE II MULTICENTER THREE COHORT STUDY OF ORAL CMET INHIBITOR INC280 IN ADULT PATIENTS WITH EGFR WILD TYPE WT ADVANCED NON SMALL CELL LUNG CANCER NSCLC WHO HAVE RECEIVED ONE OR TWO PRIOR LINES OF SYSTEMIC THERAPY FORADVANCED METASTATIC DISEASE" ($1.7M).